SHINECO, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-10-08: Form 8-K; Period of report 2025-10-01; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events; Details 3.01.
- 2025-07-31: Form 8-K; Period of report 2025-07-25; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events; Details 3.01.
- 2025-07-09: Form 8-K; Period of report 2025-07-02; Description 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 3.02.
- 2025-06-30: Form 8-K/A; Period of report 2025-06-23; Description 9.01 Financial Statements and Exhibits; Details 9.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-10-08 | 8-K | 2025-10-01 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events | 3.01 As previously reported, on June 16, 2025, Shineco Inc. (“Shineco” or the “Company”) received a staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”) for continued listing on Nasdaq. 8.01 On July 28, 2025, the Company, along with two of its shareholders (collectively, “Plaintiffs”), initiated legal proceedings against Nasdaq in the United States District Court for the Southern District of New York (Civil Action No. 1:25-cv-6159) (the “Lawsuit”). | form8-k.htm |
| 2025-07-31 | 8-K | 2025-07-25 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events | 3.01 As previously disclosed in a Form 8-K filed on June 23, 2025, on June 16, 2025, Shineco Inc. (the “Company”) received a staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”) for continued listing on Nasdaq. 8.01 On July 28, 2025, the Company and two of its shareholders (“Plaintiffs”) filed a lawsuit against Nasdaq in the United States District Court for the Southern District of New York (Civil Action No. 1:25-cv-6159) seeking an initial expedited Temporary Restraining Order (“TRO”) to enjoin Nasdaq from suspending trading and delisting the Company’s common stock (“Lawsuit”). | form8-k.htm |
| 2025-07-09 | 8-K | 2025-07-02 | 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 3.02 As previously reported on a Current Report on Form 8-K filed by Shineco, Inc. (the “Company”) filed with the Securities and Exchange Commission on June 2, 2025, the Company and certain non-U.S. investors (the “Purchasers”) entered into a securities purchase agreement (the “SPA”). 8.01 The information set forth in Item 3.02 of this Current Report on Form 8-K is incorporated herein by reference into this Item 8.01 in its entirety. | form8-k.htm |
| 2025-06-30 | 8-K/A | 2025-06-23 | 9.01 Financial Statements and Exhibits | 9.01 The audited financial statements of InfiniClone, which comprise the balance sheets as of June 30, 2024 and 2023, the related statements of operations, shareholders’ equity, and cash flows for the fiscal years ended June 30, 2024 and 2023, and the related notes to the audited financial statements, and the unaudited financial statements for the period ended March 31, 2025, are filed as Exhibit 99.1 and Exhibit 99.2 hereto and incorporated by reference herein. | form8-ka.htm |
| 2025-06-23 | 8-K | 2025-06-18 | 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 2.01 On June 18, 2025 (the “Closing Date”), Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of Shineco, Inc. (the “Company”), closed the acquisition of 51% of the equity interests in InfiniClone Limited, a company limited by shares incorporated in Hong Kong (“InfiniClone”), pursuant to the share purchase agreement (the “SPA”) dated April 22, 2025 with Dr. Lim Kah Meng, the sole shareholder of InfiniClone (the “Seller”). 3.02 The information contained in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.02 in its entirety. 8.01 The information contained in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 8.01 in its entirety. | form8-k.htm |
| 2025-06-23 | 8-K | 2025-06-16 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 16, 2025, Shineco Inc. (the “Company”) received a staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. | form8-k.htm |
| 2025-06-11 | 8-K | 2025-06-11 | 8.01 Other Events | 8.01 On June 11, 2025, Shineco, Inc. (the “Company”) announced that Ms. Jennifer Zhan, the Company’s chief executive officer, and Mr. Sai (Sam) Wang, the Company’s chief financial officer, will jointly initiate a stock purchase program (the “Stock Purchase Program”) to purchase up to $2,000,000 of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a price of up to $1.50 per share, reflecting their strong beliefs that the Common Stock is undervalued. | form8-k.htm |
| 2025-06-02 | 8-K | 2025-05-29 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.02 in its entirety. | form8-k.htm |
| 2025-05-15 | 8-K/A | 2025-05-13 | 9.01 Financial Statements and Exhibits | 9.01 The audited financial statements of FuWang (HK), which comprise the balance sheets as of June 30, 2024 and 2023, the related statements of operations, shareholders’ equity, and cash flows for the fiscal years ended June 30, 2024 and 2023, and the related notes to the audited financial statements, and the unaudited financial statements for the period ended December 31, 2024, are filed as Exhibit 99.1 and Exhibit 99.2 hereto and incorporated by reference herein. | form8-ka.htm |
| 2025-05-13 | 8-K | 2025-05-12 | 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 2.01 On May 12, 2025 (the “Closing Date”), Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of Shineco, Inc. (the “Company”), closed the acquisition of 75% of the equity interests in FuWang (HK) International Company Limited, a company limited by shares incorporated in Hong Kong (“FuWang (HK)”), pursuant to the stock purchase agreement (the “SPA”) dated March 20, 2025 with Yi Yang, the only shareholder of FuWang (HK) (the “Seller”). 3.02 The information contained in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.02 in its entirety. 8.01 The information contained in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 8.01 in its entirety. | form8-k.htm |
| 2025-04-23 | 8-K | 2025-04-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8-k.htm |
| 2025-03-20 | 8-K | 2025-03-20 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8-k.htm |